Evaluation of Prognostic Factors for Unresectable or Recurrent Gastric Cancer Treated with Nivolumab

被引：0
|
作者：
Kenji Ishido
Satoshi Tanabe
Chikatoshi Katada
Yu Ishibashi
Gen Kitahara
Mie Onoue
Yo Kubota
Yasuaki Furue
Takuya Wada
Akinori Watanabe
Chika Kusano
机构：
[1] Kitasato University School of Medicine,Department of Gastroenterology
[2] Kitasato University School of Medicine,Research and Development Center for New Medical Frontiers
来源：
Journal of Gastrointestinal Cancer | 2023年 / 54卷
关键词：
Gastric cancer; Nivolumab; Neutrophil-to-lymphocyte ratio; Immune-related adverse events;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
下载
收藏
页码：485 / 491
页数：6
相关论文
共 50 条
  • [1] Evaluation of Prognostic Factors for Unresectable or Recurrent Gastric Cancer Treated with Nivolumab
    Ishido, Kenji
    Tanabe, Satoshi
    Katada, Chikatoshi
    Ishibashi, Yu
    Kitahara, Gen
    Onoue, Mie
    Kubota, Yo
    Furue, Yasuaki
    Wada, Takuya
    Watanabe, Akinori
    Kusano, Chika
    JOURNAL OF GASTROINTESTINAL CANCER, 2023, 54 (02) : 485 - 491
  • [2] The new prognostic score for unresectable or recurrent gastric cancer treated with nivolumab: A multi-institutional cohort study
    Sato, Sho
    Oshima, Yoko
    Matsumoto, Yu
    Seto, Yasuyuki
    Yamashita, Hiroharu
    Hayano, Koichi
    Kano, Masayuki
    Ono, Hidetaka Andrew
    Mitsumori, Norio
    Fujisaki, Muneharu
    Kunisaki, Chikara
    Akiyama, Hirotoshi
    Endo, Itaru
    Ichikawa, Yasushi
    Urakami, Hidejiro
    Kubo, Hirokazu
    Nagaoka, Sakae
    Shimada, Hideaki
    ANNALS OF GASTROENTEROLOGICAL SURGERY, 2021, 5 (06): : 794 - 803
  • [3] Investigation of prognostic factors for second-line treatment with nivolumab for unresectable or recurrent esophageal cancer.
    Ogata, Takashi
    Machida, Nozomu
    Takahashi, Kosuke
    Kano, Kazuki
    Koumori, Keisuke
    Watanabe, Hayato
    Fujikawa, Hirohito
    Yamada, Takanobu
    Inokuchi, Yasuhiro
    Furuta, Mitsuhiro
    Kaneta, Yoshihiro
    Hayashi, Kei
    Ishida, Ayaka
    Oshima, Takashi
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [4] The use of ramucirumab before nivolumab may improve survival for unresectable advanced or recurrent gastric cancer
    Hirata, Shoichiro
    Kono, Yoshiyasu
    Kanzaki, Hiromitsu
    Inoo, Shoko
    Kuraoka, Sakiko
    Matsueda, Katsunori
    Okanoue, Shotaro
    Satomi, Takuya
    Hamada, Kenta
    Iwamuro, Masaya
    Kawano, Seiji
    Kawahara, Yoshiro
    ANNALS OF ONCOLOGY, 2023, 34 : S1437 - S1437
  • [5] Inflammatory prognostic factors in advanced or recurrent esophageal squamous cell carcinoma treated with nivolumab
    Ikoma, Tatsuki
    Shimokawa, Mototsugu
    Matsumoto, Toshihiko
    Boku, Shogen
    Yasuda, Tomoyo
    Shibata, Nobuhiro
    Kurioka, Yusuke
    Takatani, Masahiro
    Nobuhisa, Tetsuji
    Namikawa, Tsutomu
    Kitagawa, Hiroyuki
    Hanazaki, Kazuhiro
    Doi, Keitaro
    Shimada, Takanobu
    Tsumura, Takehiko
    Marusawa, Hiroyuki
    Kanaya, Seichiro
    Morita, Shuko
    Inokuma, Tetsurou
    Nagai, Hiroki
    Yasui, Hisateru
    Satake, Hironaga
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (02) : 427 - 435
  • [6] Inflammatory prognostic factors in advanced or recurrent esophageal squamous cell carcinoma treated with nivolumab
    Tatsuki Ikoma
    Mototsugu Shimokawa
    Toshihiko Matsumoto
    Shogen Boku
    Tomoyo Yasuda
    Nobuhiro Shibata
    Yusuke Kurioka
    Masahiro Takatani
    Tetsuji Nobuhisa
    Tsutomu Namikawa
    Hiroyuki Kitagawa
    Kazuhiro Hanazaki
    Keitaro Doi
    Takanobu Shimada
    Takehiko Tsumura
    Hiroyuki Marusawa
    Seichiro Kanaya
    Shuko Morita
    Tetsurou Inokuma
    Hiroki Nagai
    Hisateru Yasui
    Hironaga Satake
    Cancer Immunology, Immunotherapy, 2023, 72 : 427 - 435
  • [7] A multicenter study of prognostic factors in nivolumab monotherapy for advanced or recurrent esophageal cancer
    Ikoma, T.
    Satake, H.
    Matsumoto, T.
    Boku, S.
    Shibata, N.
    Takatani, M.
    Nagai, H.
    Yasui, H.
    ANNALS OF ONCOLOGY, 2021, 32 : S162 - S162
  • [8] Prognostic factors of gastric cancer treated with adjuvant radiochemotherapy
    Martin Sanchez, M.
    Perez Escutia, M. A.
    Pena Sanchez, M. C.
    Lora Pablos, D.
    Guardado Gonzalez, S.
    Pedraza Fernandez, S.
    Chavez Jimenez, T. C.
    Moreno Hurtado, A.
    Casado Jimenez, M.
    Perez-Regadera Gomez, J. P.
    RADIOTHERAPY AND ONCOLOGY, 2016, 119 : S600 - S600
  • [9] Novel Prognostic Score for recurrent or metastatic head and neck cancer patients treated with Nivolumab
    Kiyoshi Minohara
    Takuma Matoba
    Daisuke Kawakita
    Gaku Takano
    Keisuke Oguri
    Akihiro Murashima
    Kazuhiro Nakai
    Sho Iwaki
    Wataru Hojo
    Ayano Matsumura
    Shinya Ozaki
    Taijiro Ozawa
    Ikuma Harata
    Nobukazu Tanaka
    Shinichiro Maseki
    Hiroshi Tsuge
    Sae Imaizumi
    Shoji Mitsuya
    Kazuho Moribe
    Shinichi Esaki
    Shinichi Iwasaki
    Scientific Reports, 11
  • [10] Novel Prognostic Score for recurrent or metastatic head and neck cancer patients treated with Nivolumab
    Minohara, Kiyoshi
    Matoba, Takuma
    Kawakita, Daisuke
    Takano, Gaku
    Oguri, Keisuke
    Murashima, Akihiro
    Nakai, Kazuhiro
    Iwaki, Sho
    Hojo, Wataru
    Matsumura, Ayano
    Ozaki, Shinya
    Ozawa, Taijiro
    Harata, Ikuma
    Tanaka, Nobukazu
    Maseki, Shinichiro
    Tsuge, Hiroshi
    Imaizumi, Sae
    Mitsuya, Shoji
    Moribe, Kazuho
    Esaki, Shinichi
    Iwasaki, Shinichi
    SCIENTIFIC REPORTS, 2021, 11 (01)
12345